No abstract available.
Doxazosin* ; Hypertension*

No abstract available.
*Antihypertensive Agents ; *Doxazosin ; Humans ; Liver Cirrhosis

PURPOSE: An economic analysis of pharmacological therapy and transurethral resection of the prostate (TURP) for patients with benign prostatic hyperplasia (BPH) was conducted. MATERIALS AND METHODS: Twenty six patients had undergone TURP from January to June 2000 were enrolled in this study. The costs associated with this group of patients were compared with those of 7 patients treated with medication (doxazosin, terazosin, tamsulosin, and finasteride only and alpha-blocker with finasteride). RESULTS: The mean cost for TURP was 1,900,000 won. The most expensive medical therapy was finasteride, which was followed by tamsulosin, terazosin, and doxazosin, with an estimated 12-month cost of 817,000won, 695,000won, 396,000won, and 372,000won respectively. The costs associated with doxazosin remained lower than those associated with TURP for approximately 5.3 years (the corresponding break-even point was 2.4 years for finasteride vs. TURP). CONCLUSIONS: Among the pharmacological therapies, doxazosin is the most cost effective. TURP was more cost effective than doxazosin therapy after 5.3 years. In view of the cost-effectiveness, TURP may be considered as the mode of primary therapy for the patients with severe symptoms of BPH.
Doxazosin ; Finasteride ; Humans ; Prostate* ; Prostatic Hyperplasia* ; Transurethral Resection of Prostate

PURPOSE: We evaluated and compared the efficacy of terazosin, doxazosin and terazosin(alpha-1 adrenoreceptor antagonist) with finasteride(5-alpha reductase inhibitor) in the treatment of patient with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: The study was single-blind design. The patients were divided 3 groups(terazosin group, doxazosin group, terazosin with finasteride group). Terazosin was administrated with escalating dose of 1 to 5mg once daily for 12 weeks. Doxasosin, fixed dose of 2mg was taken once daily for 12 weeks. Finasteride was taken 5mg once daily with terazosin for 12 weeks. The study enrolled 69 patients, and 60 patients were included in the analyses. RESULTS: The parameters used to assess the effectiveness included international Prostatic Symptom Score(1-PSS), Quality of Life(QOL) index and peak urinary flow rate(Qmax). At baseline, 1-PSS, QOL index and Qmax were 18.8+/-4.3, 3.7+/-1.0, 8.6+/-1.7 in terazosin group, 19.3+/-3.9, 3.6+/-1.0, 7.8+/-1.8 in doxazosin group, 20.1+/-4.4, 3.8+/-1.0, 72 +/-1.6 in combination group, respectively. After 12 weeks trial, 1-PSS, QOL index and Qmax were 12.0+/-2.8, 1.9+/-0.9, 11.4+/-2.8 respectively in terazosin group, 11.3+/-3.0, 1.7+/- 0.7, 10.6+/-2.6 in doxazosin group, 10.9+/-4.0, 1.8+/-0.9, 9.8+/-1.0 in combination group, respectively. CONCLUSIONS: There was clear evidence for the efficacy of alpha-1 blocker in treating patients with bladder outlet obstruction due to BPH. There was no significant difference between alpha-1 blocker therapy alone and combination therapy with finasteride. This study showed beneficial short term results for the safety and efficacy of long acting selective alpha-1 blocker and finasteride in the management of symptomatic BPH, but if symptom and quality of life for patient were not improved, we are 1ikely to consider that early surgical therapy will be required.
Doxazosin* ; Finasteride* ; Humans ; Oxidoreductases ; Prostatic Hyperplasia ; Quality of Life ; Urinary Bladder Neck Obstruction

BACKGROUND: Exercise-induced coronary spasm is occasionally recognized in patients with variant angina, but the patterns of exercise-induced coronary spasm and its relation to clinical features are still not clear. METHODS: Eight consecutive patients with variant angina without significant stenosis of the coronary artery performed serial treadmill exercise tests during early morning, late morning, and in the afternoon. The subjects repeated the tests after administration of atropine and doxazosin or phentolamine. RESULTS: (Upon drug administration), anginal episodes with ST-segment changes (elevation 5, depression 1) Occurred repeatedly in 6 of the 8 patients during early morning; the episodes occurred in only 2 patients during the afternoon exercise test. Four patients showed exercise-induced angina and ST-segment changes during early morning but not in the afternoon, and 2 of them showed mild episodes of exercise-induced angina and ST-segment changes during late morning. Three of the four patients had the characteristic clinical history of angina in early morning during usual activities but not during daytime activities despite the activities being more strenuous. Another 2 patients showed both exercise-induced ST-segment elevation and angina in early morning and afternoon, and they had the characteristic history of more episodes at night and in early morning but only occasionally in the daytime with or without relation to activity. One of the two patients showed intermittent ST-segment elevation during the exercise test. The other two patients had exercise-induced episodes neither in the early morning nor in the afternoon; they had a characteristic history of episodes only at night during sleep but never in the early morning nor in the daytime. Atropine did not suppress the exercise-induced angina in 4 of 5 patients studied. Doxazosin or phentolamine suppressed the exercise-induced episodes in 3 of 5 patients studied but aggravated spontaneous episodes in 3 patients. CONCLUSION: These data suggest that there's possibility of presence of different patterns of exercise-induced coronary spasm, which may be induced by different mechanisms from those in spontaneous episodes in patients with variant angina.
Atropine ; Constriction, Pathologic ; Coronary Vessels ; Depression ; Doxazosin ; Exercise Test ; Humans ; Phentolamine ; Spasm*

Purpose: The aim of this study was to evaluate the effect on sexual function after finasteride, tamsulosin, doxazosin single or combination therapy according the sexual function state before these therapies. Materials and Methods: This study included 192 men with benign prostatic hyperplasia (BPH) who had neither diabetes mellitus nor hypertension. All patients were classified into 2 groups according to their erectile dysfunction (ED) severity based on IIEF-5 before treatment; the above mild ED group (severe + moderate + mild to moderate) and mild or no ED group. The patients were assessed by IIEF inventory at the baseline and 1, 3 and 6 months after finasteride, tamsulosin, doxazosin single or combination therapies, respectively. Results: In the above mild erectile dysfunction group the mean IIEF score was significantly decreased at 3 and 6 months with finasteride single therapy, at 6 months with finasteride-tamsulosin combination therapy and at 3 and 6 months with finasteride-doxazosin combination therapy (p<0.05). In the mild or no erectile dysfunction group the mean IIEF score did not change significantly with any of the medications. Conclusions: Sexual function tended to decrease in the above mild ED group with finasteride single or combination therapy. Therefore, the patients in this group should be treated carefully at the beginning of these therapies.
Diabetes Mellitus ; Doxazosin* ; Erectile Dysfunction ; Finasteride* ; Humans ; Hypertension ; Male ; Prostatic Hyperplasia*

The antihypertensive efficacy and safety of doxazosin, a selective alpha1-inhibitor, were assessed in 20 patients with essential hypertension. Doxazosin induced a clinically significant reduction in blood pressure(26.0mmHg in systolic blood pressure and 21.7mmHg in diastolic blood pressure) with similar heart rates after 12 weeks therapy. The efficacy of doxazosin therapy was successful in 17 patients(89.5%) and failed in 2 patients(10.5%). The mean dose of the efficacy evaluable patients was 4.4mg/day. most of all patients completed for 12 weeks therapy except one patients who experienced side effects sych as vertigo, dizziness and fatigue. There were no clinically significant laboratory changes before and after the doxazosin therapy. The overall lipid profile indicated a decrease in total cholesterol with increases in HDL-cholesterol. This results indicated that doxazosin given once daily is and effective antihypertensive agent with the additional action of favorably affecting blood lipid level in the treatment of mild-to-moderate hypertension.
Blood Pressure ; Cholesterol ; Dizziness ; Doxazosin* ; Fatigue ; Heart Rate ; Humans ; Hypertension* ; Vertigo

BACKGROUND AND OBJECTIVES: Doxazosin GITS (Gastrointestinal Therapeutic System) greatly minimizes the need for titration by changing the drug-delivery rate and pharmacokinetic profile. No data are available on the safety and efficacy of Doxazosin GITS among Korean hypertensive patients. This study was designed to evaluate the effectiveness and safety of Doxazosin GITS as an add-on therapy, under standard usage conditions, through a multi center study in patients with hypertension. SUBJECTS AND METHODS: A total of 595 hypertensive patients, not adequately controlled with a single agent, were enrolled into this study. The demographic profiles were gathered at the baseline, and the patients followed up at 4 and 8 week intervals for dose adjustment and for final assessment of the efficacy, respectively. The blood pressure, heart rate, fasting glucose and lipid profiles were assessed at each visit and any adverse events also observed. RESULTS: A total of 595 patients, in whom Doxazosin GITS had been administered, and evaluated at least once according to its related parameters, were analyzed to assess its safety. Of the 595 patients 534 completed this study and fulfilled the requirements for the efficacy analysis. Eight weeks after treatment, the responders (BP<140/90 mmHg or BP<130/85 mmHg in patients with diabetes) were 68.5% of the total patients and 71.3% of the hypertensive patients without diabetes. The blood pressure was significantly improved, with a mean change from the baseline of -18.9+/-19.5/-1 0.6+/-11.8 mmHg (mean+/-standard deviation expressed as SBP/DBP)(p<0.05). In addition, Doxazosin GITS showed a change in the heart rate of -1.5+/-6.8 bpm (p<0.05), and brought favorable metabolic effects, such as improved glucose metabolism and reductions in the total cholesterol and triglyceride. A total of 18 adverse events were reported among the 595 patients (3.0%), with mild to moderate severity. CONCLUSION: Doxazosin GITS as an add-on therapy significantly improved the blood pressure and heart rate, with favorable metabolic effects. Doxazosin GITS could be a safe and effective drug for hypertension not adequately controlled with a single agent.
Blood Pressure ; Cholesterol ; Doxazosin* ; Fasting ; Glucose ; Heart Rate ; Humans ; Hypertension* ; Metabolism ; Triglycerides

PURPOSE: We administered doxazosin gastrointestinal therapeutic system (GITS) to women with non-neurogenic voiding dysfunction to evaluate its therapeutic effects. MATERIALS AND METHODS: Women who had voiding dysfunctions for at least 3 mo were included. Inclusion criteria were age > or =18yr, an International Prostate Symptom Score (IPSS) > or =15, and a maximum flow rate (Qmax) <15mL/sec and/or postvoid residual (PVR) > or =150mL. Patients with neurogenic voiding dysfunction or anatomical bladder outlet obstruction were excluded. All patients were classified according to the Blaivas-Groutz nomogram. After 4 weeks, treatment outcomes were evaluated. RESULTS: Sixty-two patients were evaluated of mean age 53.8 (32-78)yr. According to the Blaivas-Groutz nomogram, 24 patients had no or mild obstruction (group A) and 38 had moderate or severe obstruction (group B). After treatment, mean IPSS decreased significantly and by more than 5 points in 42 (67.7%). Mean bother scores, Qmax, and PVR also changed significantly. Thirty-seven (59.7%) showed Qmax increases of more than 50%. No significant difference were observed between the groups in terms of IPSS, bother score, Qmax, PVR, micturition frequencies, or functional bladder capacity changes. Adverse effects related to medication were de novo stress urinary incontinence (SUI) (1 case) and underlying SUI aggravation (1 case). By satisfaction assessments, 16 patients (25.8%) were 'mainly satisfied', 31 (50%) were 'slightly satisfied', and 15 (24.2%) were 'dissatisfied'. CONCLUSION: Doxazosin GITS was found to be effective in female patients with voiding dysfunction regardless of obstruction grade. The alpha-adrenoceptor antagonists should be viewed as initial treatment option for women with a non-neurogenic voiding dysfunction.
Doxazosin* ; Female ; Humans ; Nomograms ; Prostate ; Urinary Bladder ; Urinary Bladder Neck Obstruction ; Urinary Incontinence ; Urination

PURPOSE: The doxazosin-gastrointestinal therapeutic system (GITS) greatly minimizes the need for titration by changing the drug-delivery rate and pharmacokinetic profiles. This multi-center study was designed to evaluate the efficacy and safety of doxazosin GITS in patients with BPH when used under the standard usage conditions. MATERIALS AND METHODS: A total of 487 men, aged 40 years or over, with clinical evidence of BPH were enrolled. Demographic profiles were gathered at the baseline and the patients followed up at 4 and 8 weeks for dose adjustment and final assessment of the efficacy, respectively. The efficacy, measured in terms of the International Prostate Symptom Score (IPSS), quality of life (QOL), maximum urinary flow rate (Qmax) and post-voiding residual volume were assessed on each visit. RESULTS: On completion of the study, the mean change in the IPSS and QOL from the baseline were -6.9+/-5.7 (p<0.01) and -1.4+/-1.1 (p<0.01), respectively. The Qmax and post-voiding residual volume were significantly improved compared to the baseline (p<0.01). Decreases in the mean systolic and diastolic blood pressures from the baseline in hypertensive patients (n=139) were significantly greater than in normotensive patients (n=309). There were 25 cases (5.1%) among 487 patients in which adverse events, such as dizziness, impotence, dryness of mouth and postural hypotension, were reported. CONCLUSIONS: In treating BPH, doxazosin GITS significantly improved the IPSS, QOL, Qmax and post-voiding residual volume. Doxazosin GITS is a safe and effective drug for the treatment of BPH in Korean men when used in a standard clinical setting.
Dizziness ; Doxazosin* ; Erectile Dysfunction ; Humans ; Hypotension, Orthostatic ; Male ; Mouth ; Prostate ; Prostatic Hyperplasia* ; Quality of Life ; Residual Volume